{"id":203495,"name":"BLUEBIRD BIO, INC.","slug":"bluebird-bio-inc","state":"MA","country":"United States of America","description":"","totalSpending":3470000,"filings":29,"yearlySpending":[{"year":2019,"income":570000},{"year":2020,"income":780000},{"year":2021,"income":760000},{"year":2022,"income":140000},{"year":2023,"income":830000},{"year":2024,"income":390000}],"issues":["MMM","PHA","HCR"],"firms":["BLUEBIRD BIO, INC."],"lobbyists":["MARK BATTAGLINI","JENNIFER GANTEN","SARAH ARBES","CHRISTINA HARTMAN","KRISTIN WOLFF"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","Office of Management & Budget (OMB)","Centers For Medicare and Medicaid Services (CMS)","White House Office"],"sampleDescriptions":["Alternative payment models related to novel therapies.","Alternative payment models related to novel therapies.","Issues related to the reimbursement of gene therapies; issues related to the Patient Affordability Value and Efficiency Act.","Provide guidance and strategic counsel with regard to regulations and legislation that could impact the gene therapies, drug pricing and other issues that impact the industry generally, and bluebird b","S. 2543, Prescription Drug Pricing Reduction Act: issues related to value-based payment.\nIssues related to value-based drug pricing and drug pricing in general.\nIssues related to H.R. 2507, Newborn Sc"],"years":[2019,2020,2021,2022,2023,2024]}